Jonathan Holbrook, MD
Interventional Cardiology · Provo, UTNPI 1710307384
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,476 of the $5,946 with a category attached, or 75.3%. It is spread thinly across 33 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in UT, where the typical reported total is $5,946.
Across 290 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Pfizer$915
- Actelion Pharmaceuticals US, Inc.$539
- Boehringer Ingelheim$475
- Novartis$427
- E.r. Squibb & Sons, L.L.C.$350
- plus $2K from 27 others
What the payments were for
- Grants$1,10519%
- Food & beverage$4,47675%
- Education$3656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $1,361 |
| Pfizer | 81 | $915 |
| Actelion Pharmaceuticals US, Inc. | 39 | $539 |
| Boehringer Ingelheim | 28 | $475 |
| Novartis | 24 | $427 |
| E.r. Squibb & Sons, L.L.C. | 25 | $350 |
| Abbott | 5 | $256 |
| AstraZeneca | 10 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $227 |
| Johnson & Johnson | 15 | $204 |
| Amgen | 7 | $125 |
| Heartflow, Inc. | 4 | $113 |
| Novo Nordisk | 4 | $79 |
| Lexicon Pharmaceuticals, Inc. | 3 | $63 |
| Edwards Lifesciences | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 3 | $55 |
| Bridgebio Pharma, Inc. | 2 | $52 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $51 |
| United Therapeutics Corporation | 2 | $49 |
| Merck | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Bayer | 2 | $26 |
| Altathera Pharmaceuticals LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $17 |
| Abiomed | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Biosense Webster, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Biotronik Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,946 in reported general payments places this provider in the 50th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 249 | $247,007 |
| XareltoRivaroxaban | 56 | $51,277 |
| JardianceEmpagliflozin | 40 | $32,377 |
| Repatha SureclickEvolocumab | 12 | $6,530 |
| Metoprolol Succinate | 480 | $5,725 |
| Atorvastatin Calcium | 457 | $5,553 |
| ClopidogrelClopidogrel Bisulfate | 185 | $2,432 |
| Losartan Potassium | 183 | $2,342 |
| Prasugrel Hcl | 38 | $2,282 |
| Torsemide | 97 | $2,221 |
| Carvedilol | 133 | $1,951 |
| Flecainide Acetate | 37 | $1,925 |
| Rosuvastatin Calcium | 114 | $1,861 |
| Amiodarone Hcl | 66 | $1,577 |
| Ranolazine ErRanolazine | 27 | $1,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $915 | $247,007249 claims |
| Johnson & JohnsonXarelto | $204 | $51,27756 claims |
| Boehringer IngelheimJardiance | $475 | $32,37740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 45 interventional cardiology providers in Utah.
Other interventional cardiology in Provo
- Daniel BennettProvo$12K
- James FeeneyProvo$7K
- Scott BinghamProvo$1K
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
- Sanjeev TrehanOgden$95K
- Stavros DrakosSalt Lake City$79K
- Tareq HarbOgden$27K
- Frederick WeltSalt Lake City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.